Business Wire·May 13, 2026, 8:15 AM ET

QT Imaging Reports First Quarter 2026 Revenue of $6.5 Million

QT Imaging reported first-quarter 2026 revenue of $6.5 million, a 133% increase year-over-year, driven by shipping 13 Breast Acoustic CT scanners.
The company extended the maturity date of its senior secured term loan by two years to March 31, 2029, while increasing the annual interest rate to 12.0%.
QT Imaging secured a Category III CPT code (X579T) for its technology, effective January 1, 2027, facilitating future U.S. reimbursement.
The U.S. FDA granted 510(k) clearance for scanner enhancements designed to improve visualization of posterior breast tissue.
Regulatory clearance was obtained in the United Arab Emirates, supporting a multiyear agreement with minimum orders totaling 43 scanners valued at over $24 million.
The company launched the QT Imaging-Olea Viewer to unify multi-modality imaging viewing & released software version 4.5.0 to improve image reconstruction quality.
Net loss for the quarter was $3.4 million ($0.25 per share), a significant improvement from the $11.1 million loss ($1.21 per share) recorded in the same period of 2025.
Gross margin decreased to 41% from 65% in the prior-year period due to the sale of depreciated scanners in 2025.
QT Imaging reaffirmed its 2026 revenue guidance of approximately $39 million, reflecting global scanner shipments & initial cloud platform revenue.
The company uplisted to the Nasdaq Capital Market & appointed Dr. Mary W. Yamashita & Dr. Barry Roseman to its medical advisory board.